The findings revealed that the mutation population of ATR, BLM, and MLH1 appears more sensitive to Olaparib….Furthermore, mutations in ATR, BLM, and MLH1 or the expression of POLR2L, PMS1, FANCE, and other genes significantly influence Olaparib sensitivity, which may be underlying therapeutic targets in the future....Intriguingly, we discovered that the expression of POLR2L, PMS1, FANCE, WRN, and other genes was closely related to Olaparib sensitivity, suggesting that these genes may be underlying therapeutic targets in clinical practice.